Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...
MICHAEL MCCOY The Swiss drug firm Novartis has agreed to acquire a company it cofounded. Novartis will buy Anthos Therapeutics, a Boston-based biotech focused on cardiac conditions, for an up front ...
Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...
On the political front, Robert F. Kennedy Jr. will become the next HHS secretary after he attained a majority of Senate votes ...
We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...
RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...
In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...
Dealbreaker on MSN9d
Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood ClotsThe Anthos Therapeutics acquisition represents a homecoming for its drug abelacimab, which originated in Novartis’s labs.
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...
Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...
The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback